MAPK pathway inhibition in melanoma: Resistance three ways

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 727-732

  Wellbrock, Claudia ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BRAF; Drug resistance; Melanoma; Microphthalmia associated transcription factor (MITF); Mitogen activated protein kinase pathway (MAPK pathway); Mitogen activated protein kinase extracellular signal regulated kinase kinase (MEK)

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL POPULATION; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; FIBROBLAST; HUMAN; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84905869201     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140020     Document Type: Conference Paper

References (50)

1. Wellbrock, C. and Hurlstone, A. (2010) BRAF as therapeutic target in melanoma. Biochem. Pharmacol. 80, 561-567
2. Buscà, R. and Ballotti, R. (2000) Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res. 13, 60-69
3. Wellbrock, C., Weisser, C., Geissinger, E., Troppmair, J. and Schartl, M. (2002) Activation of p59Fyn leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J. Biol. Chem. 277, 6443-6454
4. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C.J. and Marais, R. (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342
5. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D. and Bennett, D.C. (2006) Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505
6. Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., van der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J. and Peeper, D.S. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724
7. Michailidou, C., Jones, M., Walker, P., Kamarashev, J., Kelly, A. and Hurlstone, A.F. (2009) Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model. Dis. Model. Mech. 2, 399-411
8. Wellbrock, C. and Schartl, M. (2000) Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. Eur. J. Biochem. 267, 3513-3522
9. Wu, H., Goel, V. and Haluska, F.G. (2003) PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122
10. Vredeveld, L.C., Possik, P.A., Smit, M.A., Meissl, K., Michaloglou, C., Horlings, H.M., Ajouaou, A., Kortman, P.C., Dankort, D., McMahon, M. et al. (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055-1069
11. Madhunapantula, S.V., Mosca, P.J. and Robertson, G.P. (2011) The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol. Ther. 12, 1032-1049
12. Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhim, R., Milner, D.A., Granter, S.R., Du, J. et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122
13. Levy, C., Khaled, M. and Fisher, D.E. (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414
14. Hemesath, T.J., Price, E.R., Takemoto, C., Badalian, T. and Fisher, D.E. (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391, 298-301
15. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T. and Marais, R. (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734
16. Wellbrock, C., Karasarides, M. and Marais, R. (2004) The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885
17. Cohen, C., Zavala-Pompa, A., Sequeira, J.H., Shoji, M., Sexton, D.G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. and Arbiser, J.L. (2002) Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728-3733
18. Wellbrock, C. and Schartl, M. (1999) Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. Eur. J. Biochem. 260, 275-283
19. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954
20. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D. and Marais, R. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867
21. Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K. and Chapman, P.B. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819
22. Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T. et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714
23. Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, Jr, W.H. and Kaempgen, E. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365
24. Adjei, A.A., Cohen, R.B., Franklin, W., Morris, C., Wilson, D., Molina, J.R., Hanson, L.J., Gore, L., Chow, L., Leong, S. et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146
25. Infante, J.R., Fecher, L.A., Falchook, G.S., Nallapareddy, S., Gordon, M.S., Becerra, C., DeMarini, D.J., Cox, D.S., Xu, Y., Morris, S.R. et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 13, 773-781
26. Kirkwood, J.M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K. and Dummer, R. (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555-567
27. Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P. et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114
28. Gibney, G.T., Messina, J.L., Fedorenko, I.V., Sondak, V.K. and Smalley, K.S. (2013) Paradoxical oncogenesis: the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 10, 390-399
29. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N. et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703
30. Corcoran, R.B., Dias-Santagata, D., Bergethon, K., Iafrate, A.J., Settleman, J. and Engelman, J.A. (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84
31. Johannessen, C.M., Boehm, J.S., Kim, S.Y., Thomas, S.R., Wardwell, L., Johnson, L.A., Emery, C.M., Stransky, N., Cogdill, A.P., Barretina, J. et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972
32. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.K., Attar, N., Sazegar, H. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977
33. Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M. et al. (2013) Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167
34. Villanueva, J., Vultur, A., Lee, J.T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A.K., Wubbenhorst, B., Xu, X., Gimotty, P.A., Kee, D. et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695
35. Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.Q., Buchanan, S., Henry, J.R., Starling, J.J. and Peng, S.B. (2012) Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 287, 28087-28098
36. Montagut, C., Sharma, S.V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L.E., Dias-Santagata, D., Stubbs, H., Lee, D.Y., Singh, A. et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861
37. Whittaker, S.R., Theurillat, J.P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G.S., Schadendorf, D., Root, D.E. and Garraway, L.A. (2013) A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362
38. Nikolaev, S.I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V. et al. (2011) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139
39. Wagle, N., Emery, C., Berger, M.F., Davis, M.J., Sawyer, A., Pochanard, P., Kehoe, S.M., Johannessen, C.M., Macconaill, L.E., Hahn, W.C. et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096
40. Paraiso, K.H., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., Munko, A.C., Wood, E., Fedorenko, I.V., Sondak, V.K., Anderson, A.R. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760
41. Gopal, Y.N., Deng, W., Woodman, S.E., Komurov, K., Ram, P., Smith, P.D. and Davies, M.A. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 70, 8736-8747
42. Liu, P., Cheng, H., Roberts, T.M. and Zhao, J.J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644
43. Abel, E.V., Basile, K.J., Kugel, 3rd, C.H., Witkiewicz, A.K., Le, K., Amaravadi, R.K., Karakousis, G.C., Xu, X., Xu, W., Schuchter, L.M. et al. (2013) Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168
44. Smith, M.P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. and Wellbrock, C. (2013) Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J. Natl. Cancer Inst. 105, 33-46
45. Haq, R., Yokoyama, S., Hawryluk, E.B., Jonsson, G.B., Frederick, D.T., McHenry, K., Porter, D., Tran, T.N., Love, K.T., Langer, R. et al. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl. Acad. Sci. U.S.A. 110, 4321-4326
46. Johannessen, C.M., Johnson, L.A., Piccioni, F., Townes, A., Frederick, D.T., Donahue, M.K., Narayan, R., Flaherty, K.T., Wargo, J.A., Root, D.E. and Garraway, L.A. (2013) A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142
47. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T. et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504
48. Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J. et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509
49. Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R.C., Moriceau, G., Chodon, T., Guo, R., Johnson, D.B., Dahlman, K.B. et al. (2013) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93
50. Van Allen, E.M., Wagle, N., Sucker, A., Treacy, D.J., Johannessen, C.M., Goetz, E.M., Place, C.S., Taylor-Weiner, A., Whittaker, S., Kryukov, G.V. et al. (2013) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109